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health policy issues. The effects of each policy category were disentangled into
Price, Volume and Quality; and where an effect was identifiable, by comparing to
the intent of the policy, it was qualified by 3 sets of parameters: Direct-or-Indirect
Effect, Desired-or-Undesired Effect and Decreasing-or-Increasing Effect. RESULTS:
The identified 10 policies were grouped into 5 main categories: Essential Drug
Listing & Price Control (3), Essential Drug Usage Promotion (2), Reimbursed Drug
Listing & Price Control (2), Hospital Drug Price Controls (2), and Prescribing-Dis-
pensing Separation (1). The majority (4/5) of the policy categories were targeted
directly at lowering drug prices, and did achieve certain Direct-Desired-Decreasing
effects on Price. Three of these four policy categories, however, also had indirect-
undesired effects, mainly manifested as encouraging over-prescribing or lowering
drug quality. The other policy aimed at promoting rational pharmaceutical pre-
scribing failed to make tangible impact at national level. CONCLUSIONS: The drug
policies implemented during 2009-2011 achieved limited success and new ap-
proaches towards reform will be needed to obtain better results.
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OBJECTIVES: To investigate recent trends in reimbursement payment for phar-
macy service and pharmaceuticals from the Korean National Health Insurance
(NHI) using the NHI claims database. METHODS: Pharmacy claims data were ex-
tracted from the Korean NHI database from January 1, 2008 to March 31, 2011 by
quarterly unit. The monthly number of prescriptions of each pharmacy, the aver-
age number of supply-days per prescription, and payment amount to each phar-
macy including cost of pharmaceuticals and dispensing fees were calculated from
the claims. The information of all community pharmacies such as the number of
pharmacists in practice and pharmacy locationwas collected. The trends and vari-
ation in the pharmacy payment amount and the composition were traced on quar-
terly basis. RESULTS: Total claims of 15,996 pharmacies were included for analysis.
The monthly reimbursed payment per pharmacy increased from 29.73 million
Korean Won (KW) in 1Q 2008 to 36.41 million KW in 1Q 2011. While the increase
related to dispensing fees was 1.73 million KW per pharmacy for this period, the
amount contributing to pharmaceuticals increased from4.95million KW. The daily
number of prescriptions per pharmacist was ranged from 39.41 in 2008/3Q to 51.09
in 2009/4Q, which is below the current daily threshold for the discount of dispens-
ing fee in South Korea, 75 prescriptions per pharmacist. The average number of
supply-days per prescription was ranged from 9.12 in 2008/1Q to 11.32 in 2010/3Q.
CONCLUSIONS: While the number of prescriptions per pharmacist and supply-
days of prescriptions were relatively stable, the reimbursement amount per phar-
macy showed an increasing trend. The main source of the increase seemed to be
the payment for pharmaceuticals rather than pharmacy services.
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OBJECTIVES: The aim of this study was to compare the cost effectiveness of BMD-
(Bone Mineral Density) screening tools- RA, QUS, pDXA, QCT, and DXA, for wom-
en’s lifetime bone densitometry exam at 66 years old. METHODS: A total of 101
subjects aged in 60s’ were recruited to estimate sensitivity and specificity of each
BMD screening tool. A Markov model was developed to analyze the cost-effective-
ness of DXA, QUS, RA, pDXA, and QCT. A cohort of 10,000 women aged 66 was
constructed for each bone densitometry and a cohort of 10,000women aged 66was
also constructed as a non-exam group. In theMarkovmodel of osteoporosis and its
related fractures, costs and effectiveness measured by QALY were estimated until
the cohorts reached 100 years old or died. It was assumed that only costs were
discounted by 5% and the compliance for osteoporosis drugs was 38%. Sensitivity
analysis was performed on the discount rate and the compliance to osteoporosis
drugs. RESULTS: ICER (incremental cost-effectiveness ratio) is an indicator of how
much extra costs are needed to increase an extra 1QALY compared to the reference
group. The magnitudes of ICER’s were ordered as DXApDXA(QCT, RA, QUS).
DXA and pDXA cost extra 398,618 won and 453,947 won, respectively, in order to
increase 1 extra QALY compared to the non-exam group, which meant that DXA
and pDXA were very cost-effective. The extra costs for QUS, RA, and QCT to in-
crease 1 QALY compared to the non-exam group ranged 530,000 won‘590,000 won,
which meant that these were also cost-effective. CONCLUSIONS: All the BMD
screening tools that were examined in this study were found to be cost-effective in
terms of ICER. When the relative cost-effectiveness of pDXA, QUS, RA, and QCT
compared with DXA, DXA was predominant over the other.
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OBJECTIVES: It is not mandatory for pharmaceutical manufacturers to submit
cost-effectiveness evidence yet in Taiwan, but an incentive of a maximum 10%
mark-up for conducting local cost-effectiveness analysis has been announced
since 2010. HTA/CDE (Division of Health Technology Assessment, Center for Drug
Evaluation) assists the assessment on the strength of evidence of local cost-effec-
tiveness evaluation, and a checklist was therefore developed to ensure the consis-
tency and to improve the transparency. This study presents the impact of local
pharmacoeconomic incentive and the development of the checklist.METHODS: By
reviewing other international checklists for quality assessment of pharmacoeco-
nomic evidence and adding items for local adaptation and transferability, a check-
list consisting of four dimensions including PICOS, cost-effectiveness analysis de-
sign, source of parameters, and overall quality was developed with a four-level-
grading for evidence strength. The local pharmacoeconomic evidence was
identified from the dossiers submitted by themanufacturers during 2008-2011, and
was independently assessed by the four reviewers in the economic evaluation
team of HTA/CDE as reference cases. Discrepancies between reviewers were dis-
cussed until consensus was reached. RESULTS: There were 83 and 67 dossiers
submitted for reimbursement before and after the incentive was announced, re-
spectively. However, no local pharmacoeconomic evidence has been submitted
until eight months after the incentive was announceed. Another four dossiers
consist of five local pharmacoeconomic evaluation (one with multiple indications)
were submitted in 2011. The strengths of evidencewere graded as strong,medium,
low, and very low for 0, 1, 2, and 3 cases according to the checklist. CONCLUSIONS:
A pragmatic strategy was used to incorporate cost-effectiveness evidence into the
drug reimbursement decisions in Taiwan. Local pharmacoeconomic evidence sub-
missions increase slowly after the incentive was announced. A quality assessment
checklist was proposed. Further experience will be cumulated and discussed
among the submitting bodies, the appraisal committee members, and HTA/CDE.
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OBJECTIVES: To gain insights into health technology assessments (HTA) landscape
in Asia and to better understand international influence dynamics across intercon-
nected HTA universe. METHODS: Information on major Asian HTA agencies
(NECA, HITAP, CDE, etc) was collected and analysed at the level of four data cate-
gories: agencies, institutions, people (members) and assessments. For each cate-
gory a number of attributes were included (such as location, affiliations, member-
ships, type of technology, decision on technology). The Ni3 softwarewas applied to
add multiple types of connections between the datasets to conduct the analysis
and visualize HTA networks. The tool enabled mapping of relationship links that
represent direction and weight of influence, overlaying displayed stakeholders
with visual charts summarizing sets of quantitative values (such as number of
employees or budget) for visual patternmatching and comparison, and geographic
analysis. RESULTS: The analysis revealed the initiated collaboration between HTA
stakeholders in the Asia region. In the centre of the Asian HTA ecosystem are
located the most established agencies in Korea, Taiwan and Thailand where HTA
already yields important evidence to inform policy and practice. The visual analy-
sis revealed patterns of collaboration where agencies were 1) referring to each
other; 2) referring to the same sources and academic institutions, and 3) absorbing
the experience from well-established European HTA agencies such as NICE or
IQWIG. CONCLUSIONS: HTA has expanded globally and can be characterised by
common patterns in interactions when looking at and refining the evidence re-
quired for the reimbursment. Rapidly growing in number and in influence HTA
organizations in Asia are strengthening their abilities through collaboration with
each other, by involving independent research institutions into the HTA process
and by building upon European HTA experience.
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OBJECTIVES: To evaluate the association between medication adherence and
Health Related Quality of Life (HRQoL) among hypertension patients in Quetta city,
Pakistan. METHODS: A questionnaire based cross sectional study design was un-
dertakenwith hypertension patients attending public hospitals in Quetta city, Pak-
istan. HRQoLwasmeasured by Euroqol EQ-5D.Medication adherencewas assessed
by Drug Attitude Inventory. Descriptive statistics was used to tabulate demo-
graphic and disease related information. Spearman’s correlation was used to as-
sess the association between the study variables. All analysis was performed by
using SPSS 17.0. RESULTS: Among 385 study patients, mean age (SD) was 39.02
(6.59), with 68.8% of males dominating the entire cohort. Mean (SD) duration of
hypertension was 3.010.939 years. Forty percent (n154) had bachelor level of
education with 34.8% (n134) working in the private sector. Negative and weak
correlation (-0.77) between medication adherence and EQ-5D was reported. In ad-
dition, negative week but significant correlation (-0.120, p0.019) was observed
among medication adherence and EQ-VAS. CONCLUSIONS: No apparent relation-
ship between medication adherence and HRQoL was reported. Improved medica-
tion adherence therefore in patients with hypertension does not necessarily im-
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prove HRQoL. Factors other than medications adherence should be focused in
further studies to improve HRQoL.
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OBJECTIVES: Irritable bowel syndrome (IBS) is a relapsing, chronic functional gas-
trointestinal disorder leading to long-term disturbances on health-related quality
of life (HRQoL). Various functional and QoLmeasures have been developed to eval-
uate IBS outcomes, but none of the preference-based QoL measure has been ap-
plied and validated on Taiwanese people. This study aimed to explore the feasibil-
ity of applying preference-based HRQoL measures to IBS patients in Taiwan.
METHODS: This prospective study was conducted from July to December 2010 at
gastroenterology clinics in a regional hospital in southern Taiwan. IBS outpatients
diagnosed by Rome III criteria were invited into participate semi-structure inter-
view survey by using EuroQol (EQ-5D) questionnaire, 100-mmvisual analogue scale
(EQ-5D VAS) and standard gamble (SG) method. The EQ-5D assessment was trans-
formed into EQ-5D index using Japanese preference weight. Multiple regression
was used to assess factors associated with utilities, e.g. demographic, socioeco-
nomic status and disease severity. RESULTS: Of all, 29 participants (mean age
45.816.5 years; 62.1% female) completed QoL survey, except for one rejected SG
survey for disagreeing with SG hypothesis. Participants’ IBS subtypes include con-
stipation (n11; 37.9%), diarrhea (n16; 55.2%) and unsubtyped IBS (n2; 6.9%);
and 12 (41.4%) participants were newly diagnosed IBS and 12 had over two-year
disease history. Participants had no problem in EQ-5D survey, some expressed
difficulties in dimensions of pain/discomfort and anxiety/depression. Mean utility
derived from SG (0.850.16), EQ-5D index (0.790.15) and EQ-5D VAS (0.590.17)
were significantly different (p0.05). SG utility was significantly associated with
unsubtyped IBS and whether the IBS was newly diagnosed (p0.05).
CONCLUSIONS: IBS is well-tolerated but causing problem in anxiety/depression
and pain/discomfort in QoL survey.Mean utility of SG is higher than results derived
from EQ-5D and EQ VAS, and this finding matches previous literature. Further
validate the utility measures in more IBS patients with various subtypes and se-
verity is needed.
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OBJECTIVES: Chemotherapy offers cancer patients the potential benefits of im-
proved mortality and morbidity but may cause detrimental outcomes due to ad-
verse drug events (ADEs) that could require time-consuming, resource-intensive
and costly clinical management. To appropriately assess chemotherapy agents in
an economic evaluation, the impact of ADEs could be included in terms of their
incidence, costs of their management and valuation of the perceived disbenefits
via (dis)utility of ADEs. This review aimed to identify published studies reporting
utility values for chemotherapy-related ADEs. METHODS: A structured electronic
search combining terms for utility, utility valuationmethods and generic terms for
cancer treatment was conducted in MEDLINE and EMBASE in June 2011. Inclusion
criteria were: 1) primary data, and 2) elicitation of utility of chemotherapy-related
ADE. Two reviewers identified studies and extracted data independently. Any dis-
agreements were resolved by a third reviewer. RESULTS: Eighteen studies met the
inclusion criteria from the 853 abstracts initially identified, collectively reporting
218 utility values for chemotherapy-related ADEs. All eighteen studies used short
descriptions (vignettes) to obtain the utility values. Of the 218 utility values, 178
were elicited using SG or TTO while 40 were elicited using VAS. There were 169
utility values of specific chemotherapy-related ADEs (with the top ten being anae-
mia (34 values), nausea and/or vomiting (32 utility values), neuropathy (21 values),
neutropaenia (12 values), diarhoea (12 values), stomatitis (10 values), fatigue (8
values), allopecia (7 values), hand-foot syndrome (5 values) and skin reaction (5
values)) and 49 of non-specific chemotherapy-related adverse events.
CONCLUSIONS: This study has summarised the current evidence base of utility
values for chemotherapy-related ADEs. Only 178 of the 218 values were elicited
using choice-basedmethods (SG & TTO) and therefore could potentially be used as
parameter inputs in an economic evaluation incorporating ADEs of a chemother-
apy agent.
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OBJECTIVES: The current study is to quantify the burden of neuropathic pain (NeP)
with respect to health status, work productivity loss, and health care resource
utilization among patients in Japan. METHODS: The 2010 Japan National Health
andWellness Survey (NHWS), a self-reported, Internet-based survey of adult Japan
population, was used as the data source for this study (N25,000). All respondents
were categorized as those reporting either NeP, a form of pain other than NeP, and
no pain. These groups were compared on health status (using the SF-12v2), work
productivity loss (using the WPAI), and health care resource use (provider visits,
hospitalizations, and emergency room (ER) visits) in the past six months using
regression modeling controlling for demographics, health behaviors, and
comorbidities. RESULTS: Of the 25,000 patients in Japan, 0.23% (n58) reported
experiencing NeP, 5.57% (n1392) reported experiencing another form of pain, and
94.20% reported experiencing no pain in the past month. Adjusting for covariates,
patients experiencing NeP reported significantly worse physical and mental com-
ponent summary scores (42.43 and 41.60, respectively) than patients experiencing
another form of pain (45.41 and 44.83, respectively) and patients without pain
(51.03 and 47.41, respectively) (all p.05). A similar pattern was observed for health
utilities (Nep0.66 vs. Other pain0.69 vs. No pain0.76). Overall work impairment
was similar between those with NeP and those with other pain (36.50% vs. 26.63%,
respectively, p.21); however, patients with NeP reported greater overall work im-
pairment than those without pain (16.50%, p.05). Patients with NeP also reported
significantly more provider visits (18.85) than those with other pain (8.21) and no
pain (4.60) (all p.05). CONCLUSIONS: Patients in Japan with NeP report signifi-
cantly worse humanistic and economic outcomes compared with those without
pain and even other forms of pain. The results suggest improved management of
NeP may have substantial health outcome benefits.
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OBJECTIVES:The incidence of cancer is on rise inMalaysia. Despite the existence of
different screening methods the response to screening is poor. The current study
aims to examine cancer patients’ perceptions towards cancer screening and early
diagnosis. METHODS: A qualitative methodology was used to collect in-depth in-
formation from consented cancer patients, recruited from February to July 2010.
After obtaining institutional ethical approval, patients with different types and
stages of cancer from the three major ethnic groups (Malay, Chinese and Indian)
were approached. Twenty semi-structured interviews were conducted. All inter-
views were audio taped, transcribed verbatim and translated into English for the-
matic content analysis. RESULTS: Thematic content analysis yielded four major
themes: Awareness on cancer screening, perceived benefits of cancer screening,
perceived barriers to cancer screening and cues to action. Majority of the respon-
dents had never heard of cancer screening before the diagnosis. Some accounted of
heedingmammogram and pap-smear tests but did not undergo screening due to a
lack of personal susceptibility. Those who have had negative results of screening
prior to diagnosis perceived such tests as untrustworthy. Lack of knowledge and
financial constrains were reported as barriers to cancer screening. Finally, numer-
ous suggestions were given to improve screening behaviour among healthy indi-
viduals, including role of mass media in disseminating the message ‘prevention is
better than cure’. CONCLUSIONS: Patients’ narratives revealed some significant is-
sues that were in line with the health belief model which could explain negative
health behaviour. The description of the personal experiences with the cancer
could provide many cues to action for those who have never encountered this
potentially deadly disease if incorporated into health promotion activities.
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OBJECTIVES: Rural patients in China requiring cardiac and vascular interventional
treatment typically have to travel to an urban “tier3” hospital for treatment instead
of using their local “tier2” hospital due to lack of equipment. To understand the
economic drivers of improved patient access in China a pilot study was initiated.
METHODS: Data were collected on patient numbers, clinical and social groups,
insurance type, reimbursement rates, and travel costs as well as distance travelled
for a period six months before and after installation of equipment in the tier2
hospital. RESULTS: The hospitals chosen were Fengnan Hospital (tier2) and Gon-
gren Hospital (tier3) in Tangshan City and were only 13KM apart. Tier3 hospital
patients are reimbursed 55%, 65% and 80% for rural patients (43%), urban resident
(29%) and urban workers (18%) respectively. 10% of patients are not covered by
insurance and pay all costs. Tier2 hospital patients are reimbursed 70%, 75% and
85%. In the tier3 hospital during the 6 months before the equipment was installed,
1700 patients were treated at an average cost to the patient of 2905 CNY. In tier 2
hospital in the six months following installation, 107 patients were treated at an
average cost of 1925 CNY/patient, saving 980 CNY direct cost per patient or 34%. In
addition travel costs were reduced by 31 CNY/patient. CONCLUSIONS: The varia-
tion in reimbursement strategy for tier2 and tier3 hospitals offer the best financial
opportunity for improving access to treatment for patients, however further work
is needed to compare regional differences and also the effect of patients having to
travel greater distances.
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